Harbin Pharmaceutical Group Holding Co., Ltd. (600664) – Financial and Strategic SWOT Analysis Review

Harbin Pharmaceutical Group Holding Co., Ltd. (600664) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
30
Pharmaceuticals and Healthcare
China

Harbin Pharmaceutical Group Holding Co., Ltd. (600664) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Harbin Pharmaceutical Group Holding Co., Ltd. (HPGC) is a vertically integrated pharmaceutical company. It conducts the research, development, manufacture and distribution of pharmaceutical products. HPGC operates through seven business segments, namely, antibiotics, small-molecular drug preparations, modern Chinese medicines, biopharmaceuticals, OTC and healthcare products, animal vaccines and medicine circulations. HPGC is a state controlled Sino-foreign equity joint venture

Harbin Pharmaceutical Group Holding Co., Ltd. Key Recent Developments

Apr 30, 2014 Harbin Pharma Announces Dividend Payment For FY 2013
Jan 23, 2014 Harbin Pharma Announces Net Profit Outlook For FY 2013

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Harbin Pharmaceutical Group Holding Co., Ltd. – Key Facts 6
Harbin Pharmaceutical Group Holding Co., Ltd. – Key Employees 7
Harbin Pharmaceutical Group Holding Co., Ltd. – Major Products and Services 8
Harbin Pharmaceutical Group Holding Co., Ltd. – History 9
Harbin Pharmaceutical Group Holding Co., Ltd. – Locations And Subsidiaries 10
Head Office 10
Other Locations & Subsidiaries 10
Section 2 – Company Analysis 11
Harbin Pharmaceutical Group Holding Co., Ltd. – Business Description 11
Harbin Pharmaceutical Group Holding Co., Ltd. – Corporate Strategy 12
Harbin Pharmaceutical Group Holding Co., Ltd. – SWOT Analysis 13
SWOT Analysis – Overview 13
Harbin Pharmaceutical Group Holding Co., Ltd. – Strengths 13
Strength – Generic Product Portfolio 13
Strength – Focussed Research and Development 13
Strength – Cost Control 13
Harbin Pharmaceutical Group Holding Co., Ltd. – Weaknesses 14
Weakness – Decline in Revenue 14
Harbin Pharmaceutical Group Holding Co., Ltd. – Opportunities 15
Opportunity – Emerging Markets 15
Opportunity – Growing Aged Population in China 15
Opportunity – Surging Demand for Generics 15
Harbin Pharmaceutical Group Holding Co., Ltd. – Threats 16
Threat – Stringent Government Regulations 16
Threat – Competitive Pressures 16
Threat – Uncertain R&D Outcomes 16
Harbin Pharmaceutical Group Holding Co., Ltd. – Key Competitors 17
Section 3 – Company Financial Ratios 18
Financial Ratios – Capital Market Ratios 18
Financial Ratios – Annual Ratios 19
Performance Chart 21
Financial Performance 21
Financial Ratios – Interim Ratios 22
Financial Ratios – Ratio Charts 23
Section 4 – Company’s Recent Developments 24
Apr 30, 2014: Harbin Pharma Announces Dividend Payment For FY 2013 24
Jan 23, 2014: Harbin Pharma Announces Net Profit Outlook For FY 2013 25
Section 5 – Appendix 26
Methodology 26
Ratio Definitions 26
About GlobalData 30
Contact Us 30
Disclaimer 30



List of Tables
Harbin Pharmaceutical Group Holding Co., Ltd., Key Facts 6
Harbin Pharmaceutical Group Holding Co., Ltd., Key Employees 7
Harbin Pharmaceutical Group Holding Co., Ltd., Major Products and Services 8
Harbin Pharmaceutical Group Holding Co., Ltd., History 9
Harbin Pharmaceutical Group Holding Co., Ltd., Subsidiaries 10
Harbin Pharmaceutical Group Holding Co., Ltd., Key Competitors 17
Harbin Pharmaceutical Group Holding Co., Ltd., Ratios based on current share price 18
Harbin Pharmaceutical Group Holding Co., Ltd., Annual Ratios 19
Harbin Pharmaceutical Group Holding Co., Ltd., Interim Ratios 22
Currency Codes 26
Capital Market Ratios 26
Equity Ratios 27
Profitability Ratios 27
Cost Ratios 28
Liquidity Ratios 28
Leverage Ratios 29
Efficiency Ratios 29



List of Figures
Harbin Pharmaceutical Group Holding Co., Ltd., Performance Chart (2010 – 2014) 21
Harbin Pharmaceutical Group Holding Co., Ltd., Ratio Charts 23

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.